This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study
by Zacks Equity Research
MRK's investigational TROP2-directed ADC, sac-TMT, achieves key survival goals in a phase III endometrial cancer study.
MRKNegative Net Change LQDANegative Net Change IMCRNegative Net Change
pharmaceuticals
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
by Zacks Equity Research
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.
LQDANegative Net Change VTRSPositive Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
by Kinjel Shah
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
SNYNegative Net Change BMYPositive Net Change NVOPositive Net Change TEVAPositive Net Change
pharmaceuticals
J&J's Pipeline Progress & New Drugs Promise Stronger Long-Term Growth
by Kinjel Shah
J&J's expanding pipeline, new drug approvals and rising sales from cancer medicines are expected to fuel growth.
JNJNegative Net Change ABBVNegative Net Change PTGXNegative Net Change
pharmaceuticals
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention
by Zacks Equity Research
BAYRY gains FDA Priority Review for asundexian NDA after phase III data showed a 26% cut in ischemic stroke risk without more major bleeding.
BAYRYNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
by Zacks Equity Research
REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.
REGNNegative Net Change BMYPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth
by Sundeep Ganoria
ABBV's neuroscience sales jump 26% in Q1, driven by Vraylar, migraine drugs and Botox as new therapies fuel growth.
BIIBNegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
Cancer Stocks That Are Advancing the Future of Oncology Care
by Kinjel Shah
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
AZNPositive Net Change NVSNegative Net Change JNJNegative Net Change PFEPositive Net Change VSTMPositive Net Change SMMTPositive Net Change XLONegative Net Change
cancer pharmaceuticals
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer
by Zacks Equity Research
RHHBY wins FDA approval for Tecentriq label expansion as a ctDNA-guided adjuvant therapy for bladder cancer patients at high risk of recurrence.
RHHBYPositive Net Change AMRNPositive Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?
by Kinjel Shah
AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart.
AZNPositive Net Change ABBVNegative Net Change
pharmaceuticals